Contract beds are an indicator of commercial demand. The number of contracted beds within a residential aged care or healthcare provider facility represents their capacity. Dementia-specific beds are beds allocated for those residents living with dementia.
PainChek® contracts all beds in a facility for ease of use.
Contracted beds is a leading indicator of demand and these commercial agreements often take time to roll out and fully train the facilities and staff.
Pain assessments are a lagging indicator of clinical utility, and we have completed 5,000,000+ pain assessments.
That’s a strong indication of good growth in clinical utility.
Remember on average around 40-50% of residents are unable to self-report their pain and therefore need access to PainChek® but we contract across all beds in a facility for ease of use – so that’s another factor that needs consideration.
Pain assessments are a duty of care in aged care and hospitals and are carried out as needed and clinical practice differs from one aged care home to another based on their protocols. So there is no average or standard to compare utility from one home to another.
It depends on the provider. This can be within a few days for smaller providers, ranging up to 4-6 weeks for larger providers. Once you’re ready to get started with PainChek® we begin the process of setting up your technology, integrating with your Care Management System, and getting all of your staff up to speed through a face to face and online training program.
PainChek® is a fast, accurate and consistent pain assessment tool for people use with people with cognitive impairment or dementia.
PainChek® uses the camera of a smart device to see and assess a person’s face, analysing it using an Artificial Intelligence (AI) system. The AI system then automatically recognises and documents facial muscle movements that are indicative of pain.
Next, the caregiver uses PainChek® to record their observations of pain related behaviours such as how the person is moving and vocalising in a simple binary (yes/no) format. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to quickly understand the levels of pain experienced by the person, and monitor the effect of medication and treatment over time.
PainChek® is a truly global company, with clients in the United Kingdom, Australia, New Zealand and Singapore and Canada.
PainChek® is continuing to expand its global footprint, with regulatory approval also granted in the EU, and regulatory review processes in progress in both the United States.
The science that underpins PainChek® is an evolution of long-established clinical standards, underpinning the most commonly used pain assessment tools for people who are unable to self-report their own pain.
Derived from independent research conducted at Curtin University in WA by an international team, the principles on which PainChek® operates, and the application itself, have been formally and extensively studied. The outcomes of these studies demonstrate not only the accuracy and consistency of PainChek®, but also its value beyond the capabilities of historical tools.
In light of this, PainChek® has been approved as a medical device in Australia, New Zealand, Singapore, the UK, EU, Canada and Malaysia, with additional international approval processes currently in progress.
If you’d like to learn more about the research which underpins PainChek®, you can click here to view the full text of all PainChek® clinical studies.
PainChek® is a software as a service technology that is deployed in the cloud and is not subject to territories or borders that can impact on supply to clients around the globe. PainChek® can be downloaded as an App remotely by all clients, typically from the Apple Store or Google Play Store and installed without the need for direct faced to face contact, thereby minimising the impact of any potential supplier entry restrictions imposed by customers.
Though many of PainChek®‘s clients operate in the residential aged care space, PainChek®‘s approval as a medical device is not limited to those with cognitive impairment and dementia — PainChek®‘s approval extends to the assessment of pain of anyone who is unable to self-report their own pain. This covers not only long term changes in cognitive ability, but also the impacts of short term deliriums and other conditions, making PainChek® a powerful tool in residential aged care, home care, or an acute care setting.
Beyond PainChek®‘s application in assessing the pain of adults, PainChek® have developed an equivalent tool for the assessment of pain in pre-verbal children. Currently in clinical trials, the PainChek® Children’s app will give parents and carers never before seen insights into the pain of pre-verbal children, fundamentally changing the way pain management for children is approached.
PainChek® is designed to support the day-to-day clinical work conducted by nurses and carers, ensuring that any pain assessment conducted results in the most accurate and consistent outcome possible.
Current pain assessment methods are manual, paper-based, and often not consistently used at the point of care by different staff members, which may result in varying assessment results. PainChek® automates the pain assessment process and improves the clinical practice of pain management, making it easier for all carers and staff to accurately assess pain without any specialist knowledge. Learn more about the evolution of pain assessment here.
We recommend that PainChek is used any time you would typically conduct a pain assessment with someone who is unable to express their own pain. If in doubt, the PainChek Clinical team can help you ensure that your policies and procedures reflect modern best practice.
